NewLink Genetics Corporation (NLNK) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 6 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
NewLink Genetics Corporation (NLNK) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $23 and the lowest price target forecast is $10. The average forecast of all the analysts is $17.83 and the expected standard deviation is $5.46.
For the current week, the company shares have a recommendation consensus of Buy. NewLink Genetics Corporation (NASDAQ:NLNK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.54 and $10.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $10.79. The buying momentum continued till the end and the stock did not give up its gains. It closed at $10.58, notching a gain of 1.34% for the day. The total traded volume was 170,326 . The stock had closed at $10.44 on the previous day.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Newlink Genetics Corp, Talarico Ernest Iii had purchased shares worth of $50,081 in a transaction dated on June 6, 2016. A total of 4,065 shares were purchased at a price of $12.32 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune systems tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.